人脑胶质瘤导向诊断的临床价值(附31例临床分析)  

The Clinical Value of Target Diagnosis of Human Brain Glioma-An Analysis of 31 Cases

作　　者：黄强[1] 杨伟廉[1] 兰青[1] 李晓楠[1] 钱志远[1] 陈坚[1] 杜子威[1] 何广仁[2] 韦永新[3] 陈晓梅[4] 

机构地区：[1]苏州医学院附属第二医院神经外科,215004 [2]苏州医学院附属第二医院核医学科,215004 [3]苏州医学院附属第二医院脑神经研究室,215004 [4]苏州医学院附属第二医院脑肿瘤研究室,215004

出　　处：《江苏医药》1994年第5期234-236,共3页Jiangsu Medical Journal

基　　金：核工业85攻关基金

摘　　要：报告31例颅内占位患者，用本院研制的导向显像剂131I—SZ39，静脉注射后72小时进行SPECT扫描，与X－CT对比，分析其对胶质瘤的定性诊断价值。结果，根据手术和病理学诊断证实的24例分析，导向SPECT的报告正确率为21／24（90％）。与此相对照的X－CT，除少数典型病例外，大多数仅疑诊胶质瘤。31 patients with intracranial space occupying lesions were scintscaned by SPECT at 72 hours afterintravenous injection of 131 I -MAb SZ-39. The results were compared with that of X-CT. The definitive diagnosticvalue of SPECT for glioma was analysed. According to the results of 24 cases confirmed by operation andhistopathologioal examination,the correct rate of SPECT target diagnosis is 21/24 (90% ). In contrast to X-CT,most cases could not be definitely diagnosed as glioma except for a few typical cases.

关 键 词：脑肿瘤 单克隆抗体 放射性核素 影像学诊断 

分 类 号：R739.4[医药卫生—肿瘤]